Lipid-Modified Immune Response Modifiers for Cytokine Biosynthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that can effectively modulate the immune response by inducing or inhibiting cytokine biosynthesis, which is crucial for treating various disorders such as viral diseases, neoplastic diseases, and autoimmune diseases.
Innovation Solution
Development of a new class of immune response modifier compounds covalently bound to an R1 group, specifically designed to induce or inhibit cytokine biosynthesis, which are administered to animals to treat a variety of conditions by modulating the immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immune response modifiers are used, then immune response modulation is achieved, but the therapeutic efficacy is insufficient for treating viral, neoplastic, and autoimmune diseases
Solution Approach 1:
The patent applies local quality by modifying specific regions of the imidazoquinoline molecule with lipid groups at particular positions (N-1, C-2, or N-4), creating compounds with localized functional enhancements that improve therapeutic efficacy while maintaining selective immune modulation properties
Solution Approach 2:
The invention creates composite molecular structures by combining imidazoquinoline core compounds with lipid moieties to form lipid-conjugated immune response modifiers. This composite approach integrates the immunomodulatory properties of the imidazoquinoline with the membrane-interaction capabilities of lipids, thereby enhancing therapeutic efficacy and cellular uptake
2Reliability
If immune response modifiers are designed to induce cytokine biosynthesis, then therapeutic benefits are achieved, but the complexity of compound structure increases
Solution Approach 1:
The patent segments the immune response modifier into distinct functional modules: the imidazoquinoline core responsible for TLR7/8 activation and cytokine induction, and the lipid moiety responsible for membrane interaction and cellular uptake. This segmentation allows independent optimization of each component while maintaining overall therapeutic efficacy
Solution Approach 2:
The lipid moiety acts as an intermediary that facilitates the interaction between the imidazoquinoline core and cellular membranes. This intermediary function enhances cellular uptake and positioning of the active pharmacophore without requiring complex structural modifications to the core immunomodulatory agent
Data Source
AI summary
Lipid-modified immune response modifier compounds, pharmaceutical compositions containing the compounds and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.